Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Limbo Land For Sarepta, Duchenne And Rare Diseases

Executive Summary

While investors were hopeful the FDA's delay in issuing its verdict for Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy medicine eteplirsen may mean the agency is not prepared to reject it, the postponement may create more doubt and uncertainty about the path forward in rare disease drug development in general.

You may also be interested in...



Data Trumps Anecdotes, Emotion At Sarepta Panel

At a highly charged April 25 meeting of the FDA's Peripheral and Central Nervous System (PCNS) Advisory Committee, which concluded with angry shouting from parents and patient advocates, a majority of panelists said Sarepta Therapeutics Inc. failed to provide sufficient efficacy data for its Duchenne muscular dystrophy drug eteplirsen to win US approval – accelerated or standard, although the votes were much closer on the former than on the latter question.

Sarepta Lashed Again; More Duchenne Market Doubt

The FDA has appeared to be in a love-hate relationship with Sarepta Therapeutics Inc.

Duchenne Market Gets Bleaker With Sarepta Eteplirsen Delay

Adding to the already bleak outlook for the Duchenne muscular dystrophy (DMD) market, Sarepta Therapeutics Inc. on Feb. 8 disclosed the FDA was delaying its verdict on the company's experimental drug eteplirsen until May 26 – citing a "major amendment" to the new drug application (NDA) submitted by the company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel